期刊文献+

基于Cu_(2)O/AuNPs构建电流型免疫传感器检测载脂蛋白A1

An amperometric immunosensor based on Cu_(2)O/AuNPs for detection of apolipoprotein-A1
下载PDF
导出
摘要 通过溶剂热法制备氧化亚铜(Cu_(2)O)纳米立方体,由原位还原氯金酸得到氧化亚铜/金纳米复合物(Cu_(2)O/AuNPs),并将其修饰于玻碳电极后,利用壳聚糖和戊二醛的酰胺键连接作用将膀胱癌肿瘤标志物载脂蛋白A1的重组抗体(Ab)固定于电极表面制成电流型免疫传感器,当载脂蛋白A1的抗原(apolipoprotein-A1,Apo-A1)与抗体发生免疫反应后,依据Cu_(2)O氧化峰电流的降低实现对Apo-A1的定量检测.实验结果表明:在最佳实验条件下,Cu_(2)O氧化峰电流变化值与Apo-A1浓度对数在10.0 pg·mL^(-1)~10.0 g·mL^(-1)浓度范围内呈良好的线性关系.该方法成功用于实际样品检测,对膀胱癌的临床诊断具有重要意义. Cuprous oxide(Cu_(2)O)nanocube is prepared by solvothermal method,and chloroauric acid is further in-situ reduced to obtain cuprous oxide/gold nanocomposites(Cu_(2)O/AuNPs),which is modified on the glassy carbon electrode.The recombinant antibody(Ab)of apolipoprotein-A1(denoted as Apo-A1)is fixed on the surface of the electrode using the amide bond between chitosan and glutaraldehyde to fabricate an amperometric immunosensor.When the immunoreaction between Apo-A1 and Ab occures,the quantitative detection of Apo-A1 is realized based on the change of the oxidation peak current for Cu_(2)O decreased.The experimental results show that good linear relationship between the change of the oxidation peak for Cu_(2)O and the Apo-A1 concentration is obtained in the range of 10.0 pg·mL^(-1)~10.0μg·mL^(-1) under optimal conditions.The proposed method is successfully used to detect Apo-A1 in real samples with great significance to the clinical diagnosis of bladder cancer.
作者 张强艳 齐继兰 薛颖 孟飞 张晓蕾 吴春勇 刘元华 杨功俊 ZHANG Qiangyan;QI Jilan;XUE Ying;MENG Fei;ZHANG Xiaolei;WU Chunyong;LIU Yuanhua;YANG Gongjun(School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China;Jiangsu Cancer Hospital,Affiliated Cancer Hospital of Nanjing Medical University,Nanjing 210009,China)
出处 《扬州大学学报(自然科学版)》 CAS 北大核心 2022年第5期54-60,共7页 Journal of Yangzhou University:Natural Science Edition
基金 国家自然科学基金资助项目(82074128).
关键词 膀胱癌 载脂蛋白A1 氧化亚铜纳米立方体 金纳米粒 电流型免疫传感器 bladder cancer apolipoprotein-A1 Cu_(2)O nanocube gold nanoparticles amperometric immunosensor
  • 相关文献

参考文献1

二级参考文献12

  • 1Jacobs B L, Lee C T, Montie J E. Montie. Bladder cancer in 2010 ; how far have we come[J]. CA Cancer J Clin, 2010, 60 (4): 244-272.
  • 2Urquidi V, Rosser C J, Goodison S. Multiplex urinary tests for bladder cacer diagnosis[J]. Eur Med J Urol, 2013, 1: 70-73.
  • 3Ye F, Wang L, Castillo Martin M, et al. Biomarkers for bladder cancer management: present and future[J]. Am J Clin Exp Urol, 2014, 2(1): 1-14.
  • 4Hazzaa S M, Elashry O M, Afifi I K. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder[J]. PathoI Oncol Res, 2010, 16(1); 101-109.
  • 5Salama R H, Selem T H, E1 Gammal M, et al. Urina- ry tumor markers could predict survival in bladder car- cinoma[J]. Indian J Clin Biochem, 2013, 28(3) : 265 -271.
  • 6Chen C L, Lin T S, Tsai C H, et al. Identification of potential bladder cancer markers in urine by abundant- protein depletion coupled with quantitative proteomics [J]. J Froteomics, 2013, 85: 28-43.
  • 7Liu R, Tian Z, Zhang Z, et al. Evaluation of acridine orange fluorescence in exfoliative urinary cytology for diagnosing bladder carcinoma [J]. Int Urol Nephrol, 2012, 44(5): 1375-1382.
  • 8Giusti I., Iacconi P, Ciregia F, et al. Fine-needle aspi- ration of thyroid nodules: proteomic analysis to identify cancer hiomarkers[J]. J Proteome Res, 2008, 7 (9) : 4079-4088.
  • 9Tung C L, Lin S T, Chou H C, et al. Proteomics- based identification of plasma biomarkers in oral squa- mous cell carcinoma[J]. J Pharm Bioraed Anal, 2013, 75.. 7-17.
  • 10Lin C P, Chen Y W, Liu W, et al. Proteomic identifi- cation of plasma biomarkers in uterine leiomvoma[J]. Mol Biosvst, 2012, 8(4): 1136-1145.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部